✦ LIBER ✦

Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy

✍ Scribed by Constantin T. Yiannoutsos; Andrea De Luca

Book ID: 111739074
Publisher: Springer US
Year: 2001
Tongue: English
Weight: 361 KB
Volume: 7
Category: Article
ISSN: 1355-0284
DOI: 10.1080/13550280152537265

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early events in the life cycle of JC vir

Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy

✍ S. Baum; A. Ashok; G. Gee; S. Dimitrova; W. Querbes; J. Jordan; Walter J. Atwood 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 653 KB

Issues in the design of new clinical tri

Issues in the design of new clinical trials for rheumatoid arthritis therapeutics

✍ Schwieterman, William D 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 293 KB

Measuring the rate of progression in Fri

Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design

✍ Lisa S. Friedman; Jennifer M. Farmer; Susan Perlman; George Wilmot; Christopher 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner‐rated functional

Design of an individualized fixed-dose c

Design of an individualized fixed-dose clinical trial to test the antiepileptic efficacy of a plasma flunarizine concentration

✍ Gordon W. Pledger; David M. Treiman 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 758 KB

Using technology in designing clinical t

Using technology in designing clinical trials to investigate the efficacy of enhanced social engagement in MCI

✍ Hiroko Dodge; Jeffrey Kaye 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Rationale and Design of the DIPAK 1 Stud

Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

✍ Meijer, Esther; Drenth, Joost P.H.; d'Agnolo, Hedwig; Casteleijn, Niek F.; de Fi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 255 KB